Table 2 Definition and incidence of (in)appropriate antibiotic therapy in the reviewed studies
Reference | Appropriate empiric antibiotic therapy | Inappropriate empiric antibiotic therapy | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aspects of appropriate antibiotic therapy | Aspects of inappropriate antibiotic therapy | ||||||||||||||||||
Definition | According to the culture | Timing | Dose | According to guidelines | Route | Indication | Duration | No known contraindication | Frequency | Number of items | Definition | Intermediate or full in vitro resistance | Timing | Omission | Indication | Route | Number of items | % IAAT | |
Kim et al. [21]a | Y | Y | Y | N | N | Y | N | N | N | N | 3 | N | Â | Â | Â | Â | Â | Â | 76.38 |
Kang et al. [12]a | N | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Y | Y | Y | Y | N | N | 3 | 52.80 |
Micek et al. [33]a | N | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Y | Y | N | Y | N | N | 2 | 24.59 |
Luna et al. [34] | Y | Y | N | N | Y | N | N | N | N | N | 2 | Y | Y | Y | N | N | N | 2 | 68.42 |
Kim et al. [8] | Y | Y | Y | N | N | Y | N | N | N | N | 3 | N | Â | Â | Â | Â | Â | Â | 49.16 |
Scarsi et al. [22]a | Y | Y | Y | Y | Y | N | N | N | N | N | 4 | Y | Y | Y | N | N | N | 2 | 14.14 |
Marschall et al. [36]a | Y | Y | Y | N | N | N | N | N | N | N | 2 | Y | Y | N | Y | N | N | 2 | 31.6 |
Shorr et al. [37]a | Y | Y | Y | N | N | N | N | N | N | N | 2 | N | Â | Â | Â | Â | Â | Â | 76.98 |
Rodriguez-Bano et al. [38]a | Y | Y | Y | Y | N | Y | N | N | N | N | 4 | N | Â | Â | Â | Â | Â | Â | 78.95 |
Ammerlaan et al. [39]a | Y | Y | Y | N | N | Y | N | N | N | N | 3 | Y | Y | Y | Y | Y | Y | 5 | 28.14 |
Erbay et al. [19]a | Y | Y | Y | Y | Y | Y | N | N | N | N | 5 | N | Â | Â | Â | Â | Â | Â | 58.25 |
Kumar et al. [40]a | Y | Y | Y | N | N | N | N | N | N | N | 2 | Y | Y | Y | N | N | N | 2 | 19.88 |
Tseng et al. [41]a | Y | Y | N | N | N | N | Y | N | N | N | 2 | Y | Y | N | N | Y | N | 2 | 49.26 |
Micek et al. [42]a | Y | Y | Y | N | N | N | Y | Y | N | N | 4 | N | Â | Â | Â | Â | Â | Â | 31.32 |
Paul et al. [43]a | Y | Y | Y | N | N | N | N | N | N | N | 2 | N | Â | Â | Â | Â | Â | Â | 67.06 |
Joung et al. [44]a | Y | Y | Y | Y | N | Y | N | N | N | N | 4 | Y | Y | Y | N | N | N | 2 | 57.76 |
Shorr et al. [45] | N | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Y | Y | Y | Y | N | N | 3 | 31.30 |
Suppli et al. [46]a | Y | Y | Y | Y | Y | N | Y | Y | Y | N | 7 | N | Â | Â | Â | Â | Â | Â | 25.51 |
Reisfeld et al. [47]a | Y | Y | N | Y | N | N | N | N | N | Y | 3 | N | Â | Â | Â | Â | Â | Â | 39.95 |
Wilke et al. [48]a | Y | N | N | N | Y | N | N | N | N | N | 1 | N | Â | Â | Â | Â | Â | Â | 51.58 |
Lye et al. [50]a | Y | Y | N | Y | Y | N | N | N | N | N | 3 | N | Â | Â | Â | Â | Â | Â | 43.56 |
Tseng et al. [51] | Y | N | N | N | N | N | Y | N | N | N | 1 | N | Â | Â | Â | Â | Â | Â | 56.44 |
Chen et al. [52] | Y | Y | Y | N | N | N | N | N | N | N | 2 | N | Â | Â | Â | Â | Â | Â | 38.98 |
Labelle et al. [54]a | Y | Y | Y | N | N | N | N | N | N | N | 2 | N | Â | Â | Â | Â | Â | Â | 51.88 |
Chen et al. [55] | Y | Y | Y | Y | Y | Y | N | N | N | N | 5 | N | Â | Â | Â | Â | Â | Â | 27.21 |
Frakking et al. [56]a | Y | Y | Y | N | N | N | N | Y | N | N | 3 | N | Â | Â | Â | Â | Â | Â | 63.36 |
Tumbarello et al. [57]a | N | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Y | Y | N | N | N | N | 1 | 50.91 |
Total | 23 | 21 | 17 | 8 | 7 | 7 | 4 | 3 | 1 | 1 | Â | 11 | 11 | 7 | 5 | 2 | 1 | Â | Â |